iShares Genomics Immunology and Healthcare ETF
IDNA
75 hedge funds and large institutions have $46.1M invested in iShares Genomics Immunology and Healthcare ETF in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 13 closing their positions.
2.78% more ownership
Funds ownership: 29.91% → 32.69% (+2.8%)
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
0% more funds holding
Funds holding: 75 → 75 (0)
0% less capital invested
Capital invested by funds: $46.2M → $46.1M (-$153K)
9% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WBG
Wharton Business Group
Malvern,
Pennsylvania
|
+$3.81M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$1.32M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$852K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$771K |
| 5 |
PP
Prudential plc
London, England,
United Kingdom
|
+$726K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.75M |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$774K |
| 3 |
Jane Street
New York
|
-$730K |
| 4 |
Nomura Asset Management
Tokyo,
Japan
|
-$568K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$394K |
IDNA Hedge Fund Activity: Q1 2023 in Review
75 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q1 2023, worth a combined $46.1M — down 0.33% from $46.2M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IDNA positions and 13 closed out — a net gain of 1 holder — while 20 added to existing stakes and 22 trimmed.
The largest buyer was Wharton Business Group, adding an estimated $3.81M. The largest seller was Morgan Stanley, cutting an estimated $1.75M.
- 75 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $46.1M of iShares Genomics Immunology and Healthcare ETF stock for Q1 2023, down 0.33% quarter-over-quarter.
- 14 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q1 2023 and 13 closed out, a net change of +1 holder.
- The largest iShares Genomics Immunology and Healthcare ETF buyer in Q1 2023 was Wharton Business Group, an estimated $3.81M added.
- The largest iShares Genomics Immunology and Healthcare ETF seller in Q1 2023 was Morgan Stanley, an estimated $1.75M sold.
Based on aggregated 13F filings for Q1 2023.